Inogen Inc - INGN STOCK NEWS

Inogen, Inc. (NASDAQ: INGN), a medical technology firm specializing in respiratory products, announced participation in the 40th Annual J.P. Morgan Healthcare Conference. President and CEO Nabil Shabshab is set to present on January 12, 2022, at 10:30 a.m. PT. The live audio webcast will be accessible via the Investor Relations section of Inogen's website. A replay will be available for 90 days post-event. Inogen continues to utilize its Investor Relations platform for disclosing material non-public information.

Inogen, Inc. (NASDAQ: INGN) has appointed Mike Sergesketter as Interim Chief Financial Officer, effective immediately. He succeeds Alison Bauerlein, who will remain in a transitional role until the end of Q1 2022. Sergesketter brings over 40 years of finance experience, having previously served as CFO at Kimball Electronics, where he facilitated globalization strategies. Nabil Shabshab, CEO of Inogen, expressed confidence in Sergesketter’s ability to support the company's strategic evolution in respiratory care.

Inogen, Inc. (NASDAQ: INGN) reported a strong Q3 2021 performance with total revenue reaching $93.1 million, a 25.3% increase year-over-year. The domestic direct-to-consumer segment generated $36.3 million, up 24.6%, while rental revenue surged 61.3% to $12.1 million. Despite supply chain challenges, operating income was $6.4 million, and net income stood at $12.2 million, with an EPS of $0.53. However, full-year 2021 guidance remains uncertain due to ongoing semiconductor shortages affecting production and costs.

Inogen, a leader in medical technology specializing in respiratory products, announced management participation in the Stifel Virtual Healthcare Conference on November 17, 2021, at 3:20 p.m. ET. The presentation will be led by President and CEO Nabil Shabshab and CFO Alison Bauerlein. Interested stakeholders can access the webcast through the Inogen Investor Relations page, with a replay available for 90 days post-event. Inogen focuses on developing portable oxygen concentrators to support patients with chronic respiratory conditions.

Limoneira Company (NASDAQ: LMNR) announced the appointment of Elizabeth (Beth) Mora to its Board of Directors, expanding the board to 11 members, nine of whom are independent. Mora brings over 30 years of experience in finance and ESG, having held executive roles at Draper and Harvard. Her expertise is expected to enhance Limoneira's strategic direction and commitment to diversity and sustainability. Mora expressed enthusiasm for contributing to the company's long-term growth while honoring its legacy.

Inogen, Inc (NASDAQ: INGN) will announce its third quarter 2021 financial results on Thursday, November 4, 2021, after market close. The company will host a conference call at 2:00 PM PT / 5:00 PM ET for discussion. Interested parties can join by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay of the call will be available from November 4, 2021, at 4:00 PM PT until November 18, 2021, at 4:00 PM PT. Inogen provides innovative respiratory products for homecare, focusing on portable oxygen concentrators.

Inogen, Inc. (NASDAQ: INGN) has announced the appointment of Dr. Stanislav Glezer as Chief Technology Officer, overseeing R&D, Medical Affairs, and Regulatory Affairs. Dr. Glezer, who joined Inogen in June 2021, brings over 27 years of experience in medical technology. He replaces Brenton Taylor, who will transition out by April 1, 2022. CEO Nabil Shabshab praised Dr. Glezer for his contributions in enhancing product development and market strategies. The management changes are expected to drive innovation and shareholder value, with a focus on improving patient outcomes.

Inogen, Inc. (NASDAQ: INGN) has announced a partnership with Ashfield Healthcare to enhance its sales capabilities by adding around 20 dedicated sales representatives to its prescriber sales organization. The collaboration aims to improve market penetration for portable oxygen concentrators (POCs) and leverage Ashfield's proprietary insights and analytics tools to drive clinician sales performance. CEO Nabil Shabshab emphasized the importance of increasing collaboration with healthcare prescribers to enhance awareness of Inogen’s offerings. This strategy is expected to positively impact patient service in oxygen therapy.

Inogen, Inc. (NASDAQ: INGN) reported a 41.7% increase in second-quarter 2021 revenue, reaching $101.6 million, driven by strong consumer demand and improved pricing. Domestic direct-to-consumer revenue rose 35.6% to $40.9 million, while rental revenue soared 85.2% to $11.3 million. However, the company faces supply chain challenges, particularly due to semiconductor shortages, which are expected to constrain revenue growth and increase costs. As of June 30, 2021, Inogen had $250 million in cash with no debt and anticipates a net loss in the second half of 2021 due to these challenges.